Intellia Therapeutics, Inc.
NTLA
$8.84
$0.202.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 59.55% | -16.77% | -13.33% | -1.63% | -30.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.55% | -16.77% | -13.33% | -1.63% | -30.40% |
| Cost of Revenue | 7.18% | 7.58% | 9.69% | 17.14% | 3.59% |
| Gross Profit | -2.42% | -10.94% | -13.12% | -20.17% | -8.41% |
| SG&A Expenses | 8.01% | 10.12% | 16.76% | 26.00% | 29.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.36% | 8.10% | 11.12% | 18.90% | 8.09% |
| Operating Income | -3.68% | -10.76% | -13.95% | -21.48% | -12.47% |
| Income Before Tax | -7.86% | -12.94% | -12.21% | -12.79% | -1.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.86% | -12.94% | -12.21% | -12.79% | -1.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.86% | -12.94% | -12.21% | -12.79% | -1.48% |
| EBIT | -3.68% | -10.76% | -13.95% | -21.48% | -12.47% |
| EBITDA | -3.49% | -10.60% | -13.83% | -21.50% | -12.37% |
| EPS Basic | 3.09% | -1.74% | -0.33% | 0.38% | 12.31% |
| Normalized Basic EPS | 9.24% | 2.71% | 1.61% | -1.62% | 9.81% |
| EPS Diluted | 3.09% | -1.74% | -0.33% | 0.42% | 12.34% |
| Normalized Diluted EPS | 9.24% | 2.71% | 1.61% | -1.62% | 9.81% |
| Average Basic Shares Outstanding | 11.34% | 11.02% | 11.51% | 13.07% | 15.34% |
| Average Diluted Shares Outstanding | 11.34% | 11.02% | 11.51% | 13.07% | 15.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |